Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;30(3):419-26.
doi: 10.1007/s00345-011-0756-2. Epub 2011 Sep 3.

Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia

Richard-Olivier Fourcade  1 , François Lacoin, Morgan Rouprêt, Alain Slama, Camille Le Fur, Emilie Michel, Axel Sitbon, François-Emery Cotté
Affiliations

Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia

Richard-Olivier Fourcade et al. World J Urol. 2012 Jun.

Abstract

Objective: This study's aim was to describe and evaluate outcomes of medical strategies used for lower urinary tract symptoms (LUTS) treatment in general practice and to assess impact of LUTS on patients' general health-related quality of life (HRQoL).

Methods: This cross-sectional observational study was conducted by French general practitioners. Eligible patients were males aged ≥50 years, diagnosed for at least one year and currently treated for LUTS due to benign prostatic hyperplasia (BPH). Several validated questionnaires were documented by patients to assess severity of LUTS (IPSS), specific quality of life (IPSS-Q8), impact of LUTS (BII), LUTS evolution (VNS) and general HRQoL (EQ-5D).

Results: Among 1,098 patients included, 82.7% were treated with monotherapies and 17.3% with combinations. Mean treatment duration was 5.2 ± 3.2 years, and 47.2% of patients had at least one treatment modification since initiation. Patients reported diminished quality of life (IPSS-Q8 ≥3) (42.3%), persisting symptoms (IPSS-score ≥12) (35.5%), symptoms worsening (VNS-score ≤-1) (18.8%) and high bother (BII-score ≥9) (2.6%). Globally, 52.8% had at least one of these unsatisfactory outcomes. Regarding general HRQoL, mean EQ-5D utility significantly decreased with LUTS severity (mild: 0.90 ± 0.12; moderate: 0.81 ± 0.21; and severe symptoms: 0.73 ± 0.25; P < 0.001). As well, all five-dimensions of EQ-5D were significantly altered in patients with moderate-to-severe LUTS (<0.001), especially 'Pain/Discomfort' and 'Anxiety/Depression'. In multivariate analyses including age and comorbidities, EQ-5D utility index remained negatively associated with each additional unit in the IPSS-score.

Conclusions: This study shows that around half of BPH patients medically treated report unsatisfactory outcomes, suggesting consequential unmet medical needs in general practice. Also, moderate-to-severe LUTS significantly impact on general HRQoL.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Outcomes according to treatment history
Fig. 2
Fig. 2
EQ-5D results by dimension and according to IPSS severity classes: mild (1–7), moderate (8–19) and severe (20–35)
See this image and copyright information in PMC

References

    1. Robert G, Descazeaud A, Azzouzi R, Saussine C, Haillot O, Dumonceau O, et al. Impact of lower urinary tract symptoms on discomfort in men aged between 50 and 80 years. Urol Int. 2010;84(4):424–429. doi: 10.1159/000304509. - DOI - PubMed
    1. Desgrandchamps F, de la Taille A, Azzouzi A, Fourmarier M, Haillot O, Lukacs B, et al. Management of non-complicated BPH: proposition of a renewed decision tree. World J Urol. 2006;24(4):367–370. doi: 10.1007/s00345-006-0096-9. - DOI - PubMed
    1. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE, Jr, Gonzalez CM, Kaplan SA, Penson DF, Ulchaker JC, Wei JT. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–1803. doi: 10.1016/j.juro.2011.01.074. - DOI - PubMed
    1. Fourcade RO, Théret N, Taïeb C. Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries. BJU Int. 2008;101(9):1111–1118. doi: 10.1111/j.1464-410X.2008.07498.x. - DOI - PubMed
    1. Barry MJ, Fowler FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement committee of the american urological association. Med Care. 1995;33(4 Suppl):145–155. - PubMed

Publication types

MeSH terms

Substances